Q BioMed Inc. (QBIO)
Stock Price:
$1.70 USD
-0.01 (-0.58%)
Updated Aug 12, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
38.60M |
| Revenue (ttm) |
15,000 |
| Net Income (ttm) |
-12.82M |
| Shares Out |
22.71M |
| EPS (ttm) |
-0.73 |
| PE Ratio |
n/a |
| Forward PE |
172.41 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$1.70 |
| Previous Close |
$1.71 |
| Change ($) |
-0.01 |
| Change (%) |
-0.58% |
| Day's Open |
1.59 |
| Day's Range |
1.59 - 1.72 |
| Day's Volume |
22,824 |
| 52-Week Range |
0.34 - 3.75 |
More Stats
| Market Cap |
38.60M |
| Enterprise Value |
35.68M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
22.71M |
| Float |
18.96M |
| EPS (basic) |
-0.71 |
| EPS (diluted) |
-0.73 |
| FCF / Share |
-0.21 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
2.60 |
| PE Ratio |
n/a |
| Forward PE |
172.41 |
| P/FCF Ratio |
n/a |
| PS Ratio |
2,573.35 |
| PB Ratio |
330.46 |
| Revenue |
15,000 |
| Operating Income |
-11.17M |
| Net Income |
-12.82M |
| Free Cash Flow |
-4.59M |
| Net Cash |
2.92M |
| Net Cash / Share |
0.13 |
| Gross Margin |
n/a |
| Operating Margin |
-74,443.17% |
| Profit Margin |
-89,254.60% |
| FCF Margin |
-30,575.83% |
| ROA |
-323.75% |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
6.00
Current: $1.70
High
6.00
Target: 6.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -8.02 | -9.02 | -12.37 | -6.35 | -0.95 | -0.04 | - |
| Net Income | -10.28 | -9.27 | -14.54 | -7.17 | -1.09 | -0.04 | - |
| Shares Outstanding | 15.04 | 13.74 | 10.47 | 8.86 | 9.07 | 6.51 | 2.78 |
| Earnings Per Share | -0.68 | -0.67 | -1.39 | -0.81 | -0.12 | -0.01 | - |
| Operating Cash Flow | -4.11 | -6.45 | -5.58 | -1.55 | -0.09 | -0.04 | - |
| Free Cash Flow | -4.11 | -6.45 | -5.58 | -1.55 | -0.09 | -0.04 | - |
| Cash & Equivalents | 0.17 | 2.68 | 0.82 | 1.47 | 0.13 | 0.01 | 0.03 |
| Total Debt | 3.69 | 2.87 | - | 2.73 | 0.30 | - | - |
| Net Cash / Debt | -3.52 | -0.19 | 0.82 | -1.26 | -0.16 | 0.01 | 0.03 |
| Assets | 0.64 | 3.20 | 0.83 | 1.47 | 0.13 | 0.01 | 0.03 |
| Liabilities | 5.69 | 3.30 | 0.47 | 3.51 | 0.39 | - | - |
| Book Value | -5.05 | -0.11 | 0.36 | -2.04 | -0.26 | 0.01 | 0.02 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Q BioMed Inc. |
| Country |
United States |
| Employees |
1 |
| CEO |
Denis D. Corin |
Stock Information
| Ticker Symbol |
QBIO |
| Stock Exchange |
US OTC |
| Unique Identifier |
OTCMKTS: QBIO |
Description
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research for the development of novel Covid-19 therapeutics. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York.